Feb. 8, 2017
Bernstein Liebhard LLP is investigating whether the Board of Directors of Teva Pharmaceuticals Industries, Ltd. (“Teva” or the “Company”) (NYSE: TEVA) breached their fiduciary duties to the Company’s shareholders.
On February 7, 2017, amid reports of a bribery investigation, Teva announced that its Chief Executive Officer Erez Vigodman will resign. Teva shares fell approximately 6% on this adverse news.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3.5 billion for its clients. The Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times.